Biomaterials-assisted cancer vaccine delivery: preclinical landscape, challenges, and opportunities.

Expert opinion on drug delivery Pub Date : 2024-07-01 Epub Date: 2024-08-17 DOI:10.1080/17425247.2024.2388832

Minglong Chen, Yue Zhou, Yanping Fu, Qingqing Wang, Chuanbin Wu, Xin Pan, Guilan Quan

{"title":"Biomaterials-assisted cancer vaccine delivery: preclinical landscape, challenges, and opportunities.","authors":"Minglong Chen, Yue Zhou, Yanping Fu, Qingqing Wang, Chuanbin Wu, Xin Pan, Guilan Quan","doi":"10.1080/17425247.2024.2388832","DOIUrl":null,"url":null,"abstract":"Introduction: Cancer vaccines (protein and peptide, DNA, mRNA, and tumor cell) have achieved remarkable success in the treatment of cancer. In particular, advances in the design and manufacture of biomaterials have made it possible to control the presentation and delivery of vaccine components to immune cells.Areas covered: This review summarizes findings from major databases, including PubMed, Scopus, and Web of Science, focusing on articles published between 2005 and 2024 that discuss biomaterials in cancer vaccine delivery.Expert opinion: The development of cancer vaccines is hindered by several bottlenecks, including low immunogenicity, instability of vaccine components, and challenges in evaluating their clinical efficacy. To transform preclinical successes into viable treatments, it is essential to pursue continued innovation, collaborative research, and address issues related to scalability, regulatory pathways, and clinical validation, ultimately improving outcomes against cancer.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1143-1154"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17425247.2024.2388832","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/17 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Cancer vaccines (protein and peptide, DNA, mRNA, and tumor cell) have achieved remarkable success in the treatment of cancer. In particular, advances in the design and manufacture of biomaterials have made it possible to control the presentation and delivery of vaccine components to immune cells.

Areas covered: This review summarizes findings from major databases, including PubMed, Scopus, and Web of Science, focusing on articles published between 2005 and 2024 that discuss biomaterials in cancer vaccine delivery.

Expert opinion: The development of cancer vaccines is hindered by several bottlenecks, including low immunogenicity, instability of vaccine components, and challenges in evaluating their clinical efficacy. To transform preclinical successes into viable treatments, it is essential to pursue continued innovation, collaborative research, and address issues related to scalability, regulatory pathways, and clinical validation, ultimately improving outcomes against cancer.

查看原文本刊更多论文

生物材料辅助癌症疫苗递送：临床前情况、挑战和机遇。

导言：癌症疫苗（蛋白质和肽、DNA、mRNA 和肿瘤细胞）在治疗癌症方面取得了显著成效。尤其是生物材料的设计和制造技术的进步，使得控制疫苗成分向免疫细胞的呈现和传递成为可能：本综述总结了主要数据库（包括PubMed、Scopus和Web of Science）中的研究结果，重点关注2005年至2024年间发表的讨论癌症疫苗递送中生物材料的文章：癌症疫苗的开发受到几个瓶颈的阻碍，包括免疫原性低、疫苗成分不稳定以及临床疗效评估方面的挑战。要将临床前的成功转化为可行的治疗方法，就必须不断创新、开展合作研究，并解决与可扩展性、监管途径和临床验证有关的问题，最终提高抗癌效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert opinion on drug delivery

自引率

0.00%

发文量